+ Philadelphia , Pennsylvania-based Longevity Biotech and San Diego , California-based Neuropore Therapies , Inc ., will focus on pre-clinical and clinical testing of treatments to slow or stop the disease by targeting inflammation . Chronic inflammation is a hallmark of many diseases , including neurodegenerative diseases . In Parkinson ’ s , evidence suggests that chronic inflammation appears early and continues throughout the disease course .
+ Lucy Therapeutics of Cambridge , Massachusetts , is developing a therapy to correct the effects of dysfunction in mitochondria ( the cell ’ s “ power plant ”). Failure of mitochondria to work properly may lead to cellular energy crisis that ultimately contributes to the onset and / or progression of Parkinson ’ s .
Each company has agreed to repayment terms , which allow MJFF to recoup investments — and invest in other promising programs — after a company acquisition or product commercialization .
MJFF ’ s initial investment is repaid
MJFF invests in early-stage promising projects
Company acquisition or product to market
The Seed Funding Process
If successful , larger investor steps in with additional funding
Clinical trials occur
Clinical trial results are published
9